查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018847

神經血管介入器材市場：依產品類型、適應症、手術類型及最終用戶分類－2026年至2032年全球市場預測

Neurovascular Intervention Devices Market by Product Type, Indication, Procedure Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經血管介入器材市場價值將達到 45.3 億美元，到 2026 年將成長至 48.4 億美元，到 2032 年將達到 71.4 億美元，複合年成長率為 6.69%。

主要市場統計數據
基準年 2025 45.3億美元
預計年份：2026年 48.4億美元
預測年份 2032 71.4億美元
複合年成長率 (%) 6.69%

對神經血管設備的最新創新、臨床應用促進因素以及影響相關人員決策的策略考量進行了清晰而令人信服的概述。

神經血管介入器材市場格局正迅速演變，這主要得益於器械工程、影像技術和急診護理方案的整合發展。近年來，臨床醫生和器械研發人員已從漸進式改進轉向平台級創新，從根本上改變了複雜腦血管疾病的診斷、治療和管理方式。這種轉變使得相關人員比以往任何時候都更需要了解產品層面的差異化因素，以及手術流程、報銷趨勢和臨床偏好如何相互作用，進而影響器械的普及和治療效果。

材料科學的突破、診斷影像技術的整合以及不斷發展的醫療保健服務模式，是如何改變神經血管治療中的設備應用和臨床路徑的？

神經血管介入器材領域正經歷變革性的轉變，其影響不僅限於器械本身的改進，也延伸到手術流程和醫療服務模式的革新。材料科學的突破和設計的改進提升了器械的療效和安全性，使臨床醫生能夠應對以往難以處理的解剖結構和複雜病變形態。同時，影像整合和導航系統的增強縮短了手術時間，提高了器械植入的精確度。因此，符合這些治療條件的患者範圍擴大，臨床醫師對先進介入治療的信心也隨之增強。

評估新關稅政策對神經血管器械相關人員。

自2025年起，對某些醫療設備組件和成品徵收關稅將進一步增加神經血管器械相關人員的採購和供應鏈的複雜性。擁有全球製造地的製造商被迫重新評估其籌資策略和成本結構，以緩解利潤率下降並維持價格競爭力。因此，醫療系統和集團採購組織的採購團隊正在權衡短期成本增加與長期臨床價值之間的利弊，尤其對於那些能夠顯著縮短手術時間、降低併發症發生率或減少後續護理需求的器械而言。

整合細分洞察，揭示產品類型、臨床適應症、醫療保健環境和手術類型如何共同決定採用趨勢和商業性重點。

透過整合產品、適應症、終端用戶和手術流程觀點，市場區隔框架提供了切實可行的洞察。根據產品類型，每種裝置類別——栓塞劑、血流導向裝置、微導管、神經血管彈簧圈、支架和血栓除去裝置裝置——都展現出不同的臨床和商業性動態。在栓塞劑領域，液態栓塞劑和顆粒狀栓塞劑之間的差異會影響手術技術、儲存和處理注意事項以及臨床應用案例。血流導向裝置則提供了差異化的價值提案，例如“Pipeline栓塞裝置”和“Surpass血流導向裝置”，其輸送方式、徑向力和內皮化特性方面的差異會影響臨床醫生的選擇。微導管的塗層，無論是親水性塗層或聚合物塗層，都會改變操作者所依賴的觸感和導航特性。同時，在彈簧圈技術方面，可脫卸式彈簧圈和推入式彈簧圈在展開控制和重新定位方面各有優劣。球囊擴張式支架和自膨式支架平台在病灶準備和部署流程上有顯著差異，血栓切除策略也分為抽吸裝置和血栓摘取支架兩種。每種平台都有其獨特的手術成功模式，這會影響醫療機構的採購決策。

區域比較趨勢揭示了法規環境、支付方結構和臨床網路如何引導不同的產品引進和商業化路徑。

神經血管介入治療的區域趨勢反映了法律規範、醫療保健系統結構和臨床實踐模式的差異。在美洲，先進的中風系統和健全的三級醫療網路正在推動血管內治療方案的快速普及，尤其注重院前分診和院間轉運流程的整合，以最大限度地提高及時干預的效率。該地區通常為新器械的早期應用提供有利環境，前提是這些器械擁有強力的臨床證據和衛生經濟學論點。此外，支付方也越來越重視療效比較，並將其納入保險覆蓋範圍的決策考量。

透過臨床證據、生產靈活性和與醫療保健系統優先事項的策略一致性來決定市場領導地位的競爭與合作動態。

神經血管介入領域的競爭動態是由成熟的醫療設備創新者、新興的專業公司以及垂直整合的醫療技術公司共同塑造的。主要企業通常會投入巨資進行醫療設備的迭代改進、開展嚴謹的臨床試驗項目並製定廣泛的培訓舉措，以縮短醫務人員的學習曲線，並加速其在醫療機構中的應用。同時，小規模、反應更靈活的公司則經常推出差異化的材料和給藥機制，挑戰現有廠商並推動品類擴張。這種趨勢在一些特定的解剖部位和手術流程中尤其明顯，因為在這些領域，即使是微小的改善也能帶來極其顯著的臨床效益。

為確保產品設計、證據產生和商業性執行的永續採用和價值，提供切實可行的策略和營運建議。

產業領導者應採取協調一致的策略，將產品開發、證據產生和商業性執行有機結合，以加速產品上市並維持市場地位。優先考慮能夠最佳化輸送能力和手術效率的設計選擇，將引起注重縮短手術時間和提高安全性的臨床醫生的共鳴。同時，投資可靠的真實世界證據（RWE）項目和衛生經濟學分析至關重要，這有助於說服採購委員會和支付方，讓他們相信醫療設備的選擇將顯著降低整體醫療保健成本。

透明且多方面的研究途徑，結合專家訪談、文獻整合和情境測試，確保獲得可靠且可操作的見解。

本分析的調查方法融合了多種定性和定量方法，以確保其嚴謹性和有效性。關鍵資料來源包括對臨床專業人員、採購經理和產業主管的結構化訪談，從而深入了解治療流程、推廣促進因素和採購決策標準。這些訪談內容與同行評審的臨床文獻、監管申報文件和會議論文集進行交叉比對，以檢驗療效聲明並識別新興的臨床共識。

整合作為結論：將設備創新、實證策略和營運韌性連結起來，作為實現永續影響和競爭優勢的關鍵要素。

總而言之，神經血管介入領域正從漸進式改善轉向變革性創新，重塑臨床路徑、採購行為和競爭動態。器械設計和手術技術的進步正在擴大治療可能性並改善治療效果，但成功的商業化越來越需要整合臨床證據、供應鏈韌性和支付方合作的綜合策略。展望2025年的收費系統，靈活的籌資策略和更清晰地展示整體擁有成本（TCO）效益對於維持市場准入和促進臨床醫生採納至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 神經血管介入器材市場：依產品類型分類

  • 栓塞劑
    • 液態栓塞劑
    • 顆粒栓子
  • 分流器
    • 管道栓塞裝置
    • 超流分流器
  • 微導管
    • 親水塗層
    • 聚合物塗層
  • 神經血管線圈
    • 可拆卸線圈
    • 推式線圈
  • 支架
    • 氣球式
    • 自膨脹
  • 血栓除去裝置
    • 吸力裝置
    • 血栓摘取支架

第9章 神經血管介入器材市場：依適應症分類

  • 動脈瘤
  • 動靜脈畸形
  • 中風

第10章：依治療類型分類的神經血管介入器材市場

  • 栓塞術
  • 血流改道
  • 血栓切除術

第11章 神經血管介入器材市場：依最終用戶分類

  • 門診部
  • 診所
  • 醫院

第12章 神經血管介入器材市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 神經血管介入器材市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經血管介入器材市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國神經血管介入器材市場

第16章：中國神經血管介入器材市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acandis GmbH
  • Balt Group
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Carl Zeiss AG
  • Evasc Medical Systems Corp.
  • GE Healthcare
  • Imperative Care Inc.
  • Japan Lifeline Co.
  • Johnson & Johnson Services, Inc.
  • Kaneka Corporation
  • Koninklijke Philips NV
  • LivaNova PLC
  • Medikit Co., Ltd.
  • Medtronic plc
  • MicroPort Scientific Corporation
  • MicroVention, Inc.
  • Nanoflex Robotics AG
  • Penumbra, Inc.
  • Phenox GmbH by Wallaby Medical, LLC
  • Rapid Medical Ltd.
  • Stryker Corporation
  • Terumo Corporation
Product Code: MRR-ED54C46E8FA1

The Neurovascular Intervention Devices Market was valued at USD 4.53 billion in 2025 and is projected to grow to USD 4.84 billion in 2026, with a CAGR of 6.69%, reaching USD 7.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.53 billion
Estimated Year [2026] USD 4.84 billion
Forecast Year [2032] USD 7.14 billion
CAGR (%) 6.69%

A clear and engaging orientation to recent neurovascular device innovations, clinical adoption drivers, and strategic considerations shaping stakeholder decisions

The landscape of neurovascular intervention devices is evolving rapidly, driven by convergent advances in device engineering, imaging, and acute care pathways. Over the last several years clinicians and device developers have moved from incremental improvements toward platform-level innovations that change how complex cerebrovascular diseases are diagnosed, treated, and managed. These shifts have heightened the imperative for stakeholders to understand not only product-level differentiators but also how procedural workflows, reimbursement dynamics, and care setting preferences interact to shape adoption and outcomes.

This executive summary synthesizes cross-cutting trends and strategic imperatives for manufacturers, clinical leaders, and investors who operate in or adjacent to the neurovascular domain. It situates technology progress-such as enhancements in flow diversion materials and thrombectomy device deliverability-alongside evolving procedural approaches and payer considerations. By clarifying the drivers of clinical adoption and the competitive tensions across product categories and indications, the narrative aims to equip decision-makers with a clear, actionable perspective that supports prioritization of R&D, go-to-market investments, and partnership strategies.

Throughout the following sections, the analysis maintains an emphasis on practical implications, balancing technical detail with commercial context to facilitate rapid translation of insight into operational planning and resource allocation.

How material science breakthroughs, imaging integration, and evolving care delivery models are reshaping device adoption and clinical pathways in neurovascular care

The neurovascular device landscape is undergoing transformative shifts that extend beyond device-level improvements to encompass procedural paradigms and care delivery models. Material science breakthroughs and refined designs have increased device efficacy and safety profiles, enabling clinicians to tackle previously untreatable anatomies and complex lesion morphologies. Simultaneously, enhanced imaging integration and navigation systems have reduced procedural times and improved the precision of device deployment, which in turn has broadened the pool of eligible patients and increased clinician confidence in advanced interventions.

As procedural success rates and operator familiarity grow, new pathways for care are emerging, including expanded utilization in ambulatory surgical settings and the creation of multidisciplinary stroke networks that streamline triage and treatment. These systemic shifts are reinforced by an emphasis on value-based care and outcomes reporting, which incentivize devices and procedural approaches that demonstrably reduce complications, rehospitalizations, and long-term disability. Consequently, companies that align product development with measurable clinical outcomes and streamlined workflows will be better positioned to gain traction.

Finally, collaboration models between device manufacturers and clinical centers are evolving to accelerate real-world evidence generation and iterative device refinement. Strategic partnerships that integrate post-market surveillance, registries, and payer engagement are becoming essential components of commercialization strategies, reshaping how innovations migrate from regulatory approval to routine clinical practice.

Assessing the practical repercussions of new tariff policies on supply chains, procurement decisions, and commercialization strategies across neurovascular device stakeholders

The introduction of tariffs in 2025 for certain medical device components and finished goods has introduced an additional layer of procurement and supply chain complexity for neurovascular device stakeholders. Manufacturers with global manufacturing footprints have been prompted to reassess sourcing strategies and cost structures to mitigate margin erosion and maintain price competitiveness. In turn, procurement teams within health systems and group purchasing organizations are weighing the trade-offs between short-term cost increases and long-term clinical value, particularly for devices that deliver demonstrable reductions in procedure time, complication rates, or subsequent care requirements.

Immediate responses have included a re-evaluation of supplier contracts, increased emphasis on nearshoring or regional manufacturing partnerships, and selective repricing of products where contractual flexibility and payer dynamics permit. In some cases, developers have accelerated investments in design simplification and component consolidation to reduce exposure to tariffed inputs. Meanwhile, clinicians and hospital administrators are focused on preserving procedural continuity and access to best-in-class devices; therefore, strategic communication of health-economic benefits and comparative clinical outcomes has become more critical to offset procurement pressures.

Looking ahead, sustained tariff-related cost pressures will favor organizations that can demonstrate total cost of care benefits, secure resilient supply chains, and adapt commercial strategies to evolving procurement frameworks. Transparent cost-effectiveness evidence and flexible distribution agreements will be pivotal in maintaining market access under shifting trade conditions.

Integrated segmentation insights that reveal how product types, clinical indications, care settings, and procedure types jointly determine adoption dynamics and commercial priorities

The market segmentation framework yields specific insights when product, indication, end user, and procedure perspectives are integrated. Based on product type, device categories such as embolic agents, flow diverters, microcatheters, neurovascular coils, stents, and thrombectomy devices each present distinct clinical and commercial dynamics. Within embolic agents, the distinctions between liquid embolics and particulate embolics influence procedural technique, storage and handling considerations, and clinical use cases. Flow diverters show differentiated value propositions across devices such as the Pipeline Embolization Device and the Surpass Flow Diverter, where differences in deliverability, radial force, and endothelialization profiles affect clinician preference. Microcatheter coatings, whether hydrophilic or polymer-based, change the tactile and navigational characteristics that operators rely upon, while coil technologies that are detachable versus pushable define different trade-offs in deployment control and repositionability. Stent platforms that are balloon-mounted versus self-expanding present distinct lesion preparation and deployment workflows, and thrombectomy strategies split between aspiration devices and stent retrievers, each with specific procedural success patterns that inform institutional purchasing decisions.

When viewed through the lens of indication, aneurysm treatment pathways, arteriovenous malformation interventions, and acute ischemic stroke care place divergent demands on device performance, inventory management, and procedural team composition. End user segmentation-ambulatory centers, clinics, and hospitals-further modulates adoption timelines and procurement behaviors, with ambulatory centers often prioritizing streamlined, high-throughput solutions and hospitals emphasizing versatility and comprehensive inventory to support complex cases. Finally, procedure type segmentation across embolization, flow diversion, and thrombectomy highlights how procedural volume, operator expertise, and case complexity interact to determine device mix and consumable usage.

Taken together, these segmentation lenses underscore the importance of tailoring product design, training programs, and commercial messaging to the nuanced needs of each clinical and operational context, ensuring that innovations are positioned to overcome adoption barriers and deliver measurable clinical impact.

Comparative regional dynamics revealing how regulatory environments, payer structures, and clinical networks drive differentiated adoption and commercialization pathways

Regional dynamics in neurovascular interventions reflect differences in regulatory frameworks, health system architectures, and patterns of clinical practice. In the Americas, advanced stroke systems and robust tertiary care networks have facilitated rapid uptake of endovascular solutions, with a pronounced emphasis on integrating pre-hospital triage and inter-hospital transfer protocols to maximize timely intervention. This region often serves as an early adopter environment for novel devices when backed by strong clinical evidence and health-economic justification, and payers increasingly scrutinize comparative outcomes as part of coverage decisions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization in certain markets coexists with variable access and reimbursement policies in others. Clinician networks and center-of-excellence models drive adoption in major urban centers, while translation to broader populations depends on local procurement practices and reimbursement alignment. In some EMEA markets, constrained capital budgets emphasize value-based purchasing and long-term cost-of-care arguments, creating opportunities for devices that demonstrably reduce overall treatment burden.

Asia-Pacific exhibits rapid adoption in high-volume centers alongside growing domestic device development ecosystems. Health systems across the region are investing in stroke infrastructure and advanced neurointerventional training, which supports scaling of both established and newer device categories. However, fragmented regulatory pathways and diverse payer arrangements require nuanced market entry strategies, including local partnerships and region-specific clinical evidence generation. Across all regions, supply chain resilience, regulatory readiness, and evidence tailored to local practice patterns are decisive factors in successful market penetration.

Competitive and collaborative dynamics that determine market leadership through clinical evidence, manufacturing agility, and strategic alignment with health system priorities

Competitive dynamics in neurovascular interventions are shaped by a mix of established device innovators, emerging specialized firms, and vertically integrated healthcare technology companies. Leading organizations typically invest heavily in iterative device refinement, robust clinical trial programs, and broad training initiatives that reduce operator learning curves and accelerate institutional adoption. Meanwhile, smaller, agile firms frequently introduce differentiated materials or delivery mechanisms that challenge incumbents and catalyze category expansion, particularly in niche anatomies or procedural workflows where incremental improvements yield outsized clinical benefit.

Partnerships between device developers and clinical centers of excellence are a common strategic approach to generate real-world evidence and optimize device iterations based on procedural feedback. These collaborative models support faster clinical adoption by building local expertise and producing the outcome data required for payer engagement. Additionally, companies that align their commercial strategies with health system priorities-such as reducing length of stay, decreasing complication rates, or enabling same-day procedures-find it easier to secure formulary inclusion and favorable procurement terms.

Intellectual property strength, manufacturing scalability, and supply chain diversification remain decisive competitive levers. Organizations that demonstrate sustained investment in post-market surveillance, education programs, and integrated clinical support are better positioned to retain market share and expand into adjacent indications and geographies. The most resilient players combine technical excellence with operational fluency across regulatory, reimbursement, and clinical adoption channels.

Actionable strategic and operational recommendations for aligning product design, evidence generation, and commercial execution to secure sustainable adoption and value

Industry leaders should adopt a coordinated strategy that aligns product development, evidence generation, and commercial execution to accelerate adoption and defend market position. Prioritizing design choices that optimize deliverability and procedural efficiency will resonate with clinicians focused on reducing procedure time and improving safety outcomes. Concurrently, investing in robust real-world evidence programs and health-economic analyses will be critical to persuade procurement committees and payers that device selection yields measurable reductions in total cost of care.

Operationally, companies should pursue supply chain resilience by diversifying sourcing, exploring regional manufacturing partnerships, and simplifying bill-of-materials where feasible to mitigate exposure to trade fluctuations. Commercially, tailoring training and support models to end user segmentation-differentiating approaches for ambulatory centers, clinics, and hospitals-will help accelerate adoption while maintaining service quality. Strategic partnerships with leading clinical centers to develop best-practice protocols and case libraries will shorten learning curves and build trust among broader clinician cohorts.

Finally, leadership teams must maintain flexibility in pricing and contracting models to accommodate varied reimbursement environments and procurement processes. Value-based contracting, risk-sharing arrangements, and bundled payment models should be explored where outcomes data support such structures. By integrating clinical, operational, and commercial priorities into a single coherent plan, organizations can convert innovation into sustainable clinical and financial value.

A transparent and multi-method research approach that combines expert interviews, literature synthesis, and scenario testing to ensure robust, actionable insights

The research methodology underpinning this analysis integrates multiple qualitative and quantitative approaches to ensure rigour and relevance. Primary inputs include structured interviews with clinical experts, procurement leaders, and industry executives, which provide contextual understanding of procedural workflows, adoption drivers, and purchasing decision criteria. These conversations are triangulated with a review of peer-reviewed clinical literature, regulatory filings, and conference proceedings to validate performance claims and identify emerging clinical consensus.

Complementary secondary research examines device design trends, manufacturing considerations, and supply chain dynamics, with attention to changes in trade policy and regional regulatory developments. The methodology also incorporates an assessment of reimbursement and health-economic literature to frame adoption incentives and payer perspectives. Data synthesis emphasizes cross-validation across sources and a clear delineation between evidence-based findings and expert opinion, with transparency about the level of confidence for key conclusions.

Where appropriate, scenario analysis is used to explore the implications of policy shifts, supply chain disruptions, and differential adoption rates across care settings. Throughout, the approach prioritizes actionable insight, linking technical device characteristics to operational and commercial outcomes that matter to clinicians, hospital executives, and investors.

Concluding synthesis that connects device innovation, evidence strategy, and operational resilience as the keys to sustainable impact and competitive advantage

In summary, the neurovascular intervention space is transitioning from incremental refinements to transformative innovations that reshape clinical pathways, procurement behaviors, and competitive dynamics. Advances in device design and procedural technology are expanding treatment possibilities and improving outcomes, but successful commercialization increasingly requires integrated strategies that align clinical evidence, supply chain resilience, and payer engagement. The 2025 tariff landscape has amplified the need for nimble sourcing strategies and stronger articulation of total cost of care benefits to maintain market access and clinician adoption.

Segmentation-specific approaches-attuned to product nuances, indication requirements, end-user preferences, and procedural contexts-are essential to prioritize investments and craft persuasive value propositions. Regionally differentiated strategies are equally important, as regulatory, reimbursement, and care delivery frameworks materially influence adoption timing and scale. Companies that combine technical excellence with rigorous evidence programs, adaptable commercial models, and resilient operations will be best positioned to lead.

Ultimately, the path from innovation to standard of care depends on deliberate execution across clinical, commercial, and operational domains. Stakeholders who act proactively to align these elements will capture the greatest value and contribute meaningfully to improved patient outcomes in neurovascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Intervention Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Particulate Embolics
  • 8.2. Flow Diverters
    • 8.2.1. Pipeline Embolization Device
    • 8.2.2. Surpass Flow Diverter
  • 8.3. Microcatheters
    • 8.3.1. Hydrophilic Coated
    • 8.3.2. Polymer Coated
  • 8.4. Neurovascular Coils
    • 8.4.1. Detachable Coils
    • 8.4.2. Pushable Coils
  • 8.5. Stents
    • 8.5.1. Balloon Mounted
    • 8.5.2. Self Expanding
  • 8.6. Thrombectomy Devices
    • 8.6.1. Aspiration Devices
    • 8.6.2. Stent Retriever

9. Neurovascular Intervention Devices Market, by Indication

  • 9.1. Aneurysm
  • 9.2. Arteriovenous Malformation
  • 9.3. Stroke

10. Neurovascular Intervention Devices Market, by Procedure Type

  • 10.1. Embolization
  • 10.2. Flow Diversion
  • 10.3. Thrombectomy

11. Neurovascular Intervention Devices Market, by End User

  • 11.1. Ambulatory Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Neurovascular Intervention Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Intervention Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Intervention Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neurovascular Intervention Devices Market

16. China Neurovascular Intervention Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acandis GmbH
  • 17.7. Balt Group
  • 17.8. Becton, Dickinson and Company
  • 17.9. Boston Scientific Corporation
  • 17.10. Carl Zeiss AG
  • 17.11. Evasc Medical Systems Corp.
  • 17.12. GE Healthcare
  • 17.13. Imperative Care Inc.
  • 17.14. Japan Lifeline Co.
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Kaneka Corporation
  • 17.17. Koninklijke Philips N.V.
  • 17.18. LivaNova PLC
  • 17.19. Medikit Co., Ltd.
  • 17.20. Medtronic plc
  • 17.21. MicroPort Scientific Corporation
  • 17.22. MicroVention, Inc.
  • 17.23. Nanoflex Robotics AG
  • 17.24. Penumbra, Inc.
  • 17.25. Phenox GmbH by Wallaby Medical, LLC
  • 17.26. Rapid Medical Ltd.
  • 17.27. Stryker Corporation
  • 17.28. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 233. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 243. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)